We’re among the Alliance for Regenerative Medicine (ARM) leaders calling on the EU to act for the future of advanced therapies in Europe.
read moreWe’re excited to announce our participation in the BIO International Convention 2025, taking place from June 16–19 at the Boston Convention & Exhibition Center.
read moreWe are thrilled to announce our participation in the 64th AFI Symposium, taking place from June 11 to 13, 2025, at the Palacongressi di Rimini.
read moreAnemocyte, a biotech company at the forefront of advanced therapy development, is excited to join the upcoming international conference on gene therapy in Gaithersburg, MD.
read more
Altheia Science proudly announces the success of its strategic collaboration with Anemocyte, a leading developer and manufacturer of pDNA and mRNA headquartered in Italy.
read moreAnemocyte is excited to announce its participation as an attendee at TIDES USA 2025, taking place from May 19–22, 2025, at the Manchester Grand Hyatt in San Diego, California.
read moreAnemocyte announces its sponsorship and exhibition at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), from May 13–17, 2025.
read moreAnemocyte is excited to announce its participation as an exhibitor at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting, taking place from May 7 to 10 in New Orleans, Louisiana.
read moreAnemocyte is pleased to announce the opening of its new company in the United States, Anemocyte Inc., based in Miami, Florida.
read moreAnemocyte is pleased to announce its participation in the Cell & Gene Meeting on the Med 2025, taking place from April 15th to 17th at the Rome Cavalieri in Rome.
read more
Anemocyte S.r.l. Single Shareholder Private Limited-Liability Company
Via R. Lepetit, 34 21040 Gerenzano (VA) Italy | Ph: +39 02 99372311 – Fax: +39 02 99372313 | Anemocyte Inc. 1221 Brickell Avenue, Suite 1160 Miami FL 33131
VAT number: 12914940155 | Share capital € 530.000,00 fully paid | R.E.A. 276961
